Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism

Xenin-25 undergoes rapid enzyme metabolism following secretion. Early studies demonstrated bioactivity of a C-terminal hexapeptide fragment of xenin-25, namely xenin-6, which were enhanced through introduction of a reduced N-terminal peptide bond, to yield Ψ-xenin-6. The present study was undertaken...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular and cellular endocrinology 2019-10, Vol.496, p.110523-110523, Article 110523
Hauptverfasser: Craig, S.L., Gault, V.A., McClean, S., Hamscher, G., Irwin, N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 110523
container_issue
container_start_page 110523
container_title Molecular and cellular endocrinology
container_volume 496
creator Craig, S.L.
Gault, V.A.
McClean, S.
Hamscher, G.
Irwin, N.
description Xenin-25 undergoes rapid enzyme metabolism following secretion. Early studies demonstrated bioactivity of a C-terminal hexapeptide fragment of xenin-25, namely xenin-6, which were enhanced through introduction of a reduced N-terminal peptide bond, to yield Ψ-xenin-6. The present study was undertaken to define the biological actions and potential antidiabetic properties of Ψ-xenin-6. In vitro enzymatic stability, insulin and glucagon secretory activity, as well as effects on beta-cell survival were determined. Studies in mice were used to assess the impact of Ψ-xenin-6 on glucose homeostasis and satiety. Ψ-xenin-6 was resistant to murine plasma degradation. In BRIN-BD11 cells and isolated murine islets, Ψ-xenin-6 significantly stimulated insulin secretion, and prominently enhanced the insulinotropic actions of GIP. Xenin-6 and Ψ-xenin-6 had no impact on glucagon secretion, although xenin-6 partially reversed the glucagonotropic action of GIP. Further in vitro investigations revealed that, similar to GLP-1, Ψ-xenin-6 significantly augmented proliferation of human and rodent clonal beta-cells, whilst also fully protecting against cytokine-induced beta-cell cytotoxicity, with greater potency than xenin-25 and xenin-6. When administered to mice in combination with glucose, Ψ-xenin-6 significantly reduced glucose levels and enhanced glucose-induced insulin release, with a duration of biological action beyond 8 h. Ψ-xenin-6 also significantly enhanced the glucose-lowering action of GIP in vivo. In overnight fasted mice, Ψ-xenin-6 exhibited satiety actions at both 25 and 250 nmol/kg. These data demonstrates that Ψ-xenin-6 is a metabolically stable C-terminal fragment analogue of xenin-25, with a metabolic action profile that merits further study as a potential antidiabetic compound. •Xenin is a gut peptide that is metabolised to bioactive fragments such as xenin-6.•Ψ-xenin-6 is an enzymatically stable, long-acting xenin-6 analogue.•Ψ-xenin-6 augments insulin secretion and potentiates GIP-induced insulin release.•Ψ-xenin-6 has positive effects on beta-cell apoptosis and proliferation.•Ψ-xenin-6 improves glucose homeostasis and insulin secretion in mice.
doi_str_mv 10.1016/j.mce.2019.110523
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2266334859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303720719302254</els_id><sourcerecordid>2266334859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-802a116dd24661ef3ca3b7fcf73bec822d3eef1030fac887389866650d4962e33</originalsourceid><addsrcrecordid>eNp9kcuOFCEUhonROO3oA7gxLF1MtVy6KCquTGe8JJO40TWh4aB0gCqBMtPzBL6Az-UrSadmXLoiwH--k3M-hF5SsqWEijfHbTSwZYSOW0pJz_gjtKFyYJ0k_fAYbQgnvBsYGS7Qs1KOhJChZ_IpuuCU94xwuUG_r50DUwueHNYJQ7o7RV290SGccKn6EADvuwo5-qQD_g63ei6w2GmGuXoL2GX9LUKq-OGhgW4h-dSx_gr_-dWtF3GFp4RnnUyGMx_7EqBityRTffvRyeIIrd8UfInP0ROnQ4EX9-cl-vr--sv-Y3fz-cOn_bubzvBR1DYm05QKa9lOCAqOG80PgzNu4AcwkjHLARxta3DaSDlwOUohRE_sbhQMOL9Er1funKcfC5Sqoi8GQtAJpqUoxoTgfCf7sUXpGjV5KiWDU3P2UeeTokSdbaijajbU2YZabbSaV_f45RDB_qt4WH8LvF0D0Ib86SGrYjwkA9bnZkXZyf8H_xeZI5yT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2266334859</pqid></control><display><type>article</type><title>Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Craig, S.L. ; Gault, V.A. ; McClean, S. ; Hamscher, G. ; Irwin, N.</creator><creatorcontrib>Craig, S.L. ; Gault, V.A. ; McClean, S. ; Hamscher, G. ; Irwin, N.</creatorcontrib><description>Xenin-25 undergoes rapid enzyme metabolism following secretion. Early studies demonstrated bioactivity of a C-terminal hexapeptide fragment of xenin-25, namely xenin-6, which were enhanced through introduction of a reduced N-terminal peptide bond, to yield Ψ-xenin-6. The present study was undertaken to define the biological actions and potential antidiabetic properties of Ψ-xenin-6. In vitro enzymatic stability, insulin and glucagon secretory activity, as well as effects on beta-cell survival were determined. Studies in mice were used to assess the impact of Ψ-xenin-6 on glucose homeostasis and satiety. Ψ-xenin-6 was resistant to murine plasma degradation. In BRIN-BD11 cells and isolated murine islets, Ψ-xenin-6 significantly stimulated insulin secretion, and prominently enhanced the insulinotropic actions of GIP. Xenin-6 and Ψ-xenin-6 had no impact on glucagon secretion, although xenin-6 partially reversed the glucagonotropic action of GIP. Further in vitro investigations revealed that, similar to GLP-1, Ψ-xenin-6 significantly augmented proliferation of human and rodent clonal beta-cells, whilst also fully protecting against cytokine-induced beta-cell cytotoxicity, with greater potency than xenin-25 and xenin-6. When administered to mice in combination with glucose, Ψ-xenin-6 significantly reduced glucose levels and enhanced glucose-induced insulin release, with a duration of biological action beyond 8 h. Ψ-xenin-6 also significantly enhanced the glucose-lowering action of GIP in vivo. In overnight fasted mice, Ψ-xenin-6 exhibited satiety actions at both 25 and 250 nmol/kg. These data demonstrates that Ψ-xenin-6 is a metabolically stable C-terminal fragment analogue of xenin-25, with a metabolic action profile that merits further study as a potential antidiabetic compound. •Xenin is a gut peptide that is metabolised to bioactive fragments such as xenin-6.•Ψ-xenin-6 is an enzymatically stable, long-acting xenin-6 analogue.•Ψ-xenin-6 augments insulin secretion and potentiates GIP-induced insulin release.•Ψ-xenin-6 has positive effects on beta-cell apoptosis and proliferation.•Ψ-xenin-6 improves glucose homeostasis and insulin secretion in mice.</description><identifier>ISSN: 0303-7207</identifier><identifier>EISSN: 1872-8057</identifier><identifier>DOI: 10.1016/j.mce.2019.110523</identifier><identifier>PMID: 31352038</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Animals ; Beta-cell ; Cell Line ; Diabetes ; Glucagon ; Glucagon - metabolism ; Glucose - pharmacology ; Humans ; Hypoglycemic Agents - chemistry ; Hypoglycemic Agents - pharmacology ; Insulin ; Insulin Secretion - drug effects ; Insulin-Secreting Cells - metabolism ; Mice ; Neurotensin - chemistry ; Neurotensin - pharmacology ; Xenin-25 ; Xenin-6</subject><ispartof>Molecular and cellular endocrinology, 2019-10, Vol.496, p.110523-110523, Article 110523</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-802a116dd24661ef3ca3b7fcf73bec822d3eef1030fac887389866650d4962e33</citedby><cites>FETCH-LOGICAL-c396t-802a116dd24661ef3ca3b7fcf73bec822d3eef1030fac887389866650d4962e33</cites><orcidid>0000-0003-4855-964X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.mce.2019.110523$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31352038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Craig, S.L.</creatorcontrib><creatorcontrib>Gault, V.A.</creatorcontrib><creatorcontrib>McClean, S.</creatorcontrib><creatorcontrib>Hamscher, G.</creatorcontrib><creatorcontrib>Irwin, N.</creatorcontrib><title>Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism</title><title>Molecular and cellular endocrinology</title><addtitle>Mol Cell Endocrinol</addtitle><description>Xenin-25 undergoes rapid enzyme metabolism following secretion. Early studies demonstrated bioactivity of a C-terminal hexapeptide fragment of xenin-25, namely xenin-6, which were enhanced through introduction of a reduced N-terminal peptide bond, to yield Ψ-xenin-6. The present study was undertaken to define the biological actions and potential antidiabetic properties of Ψ-xenin-6. In vitro enzymatic stability, insulin and glucagon secretory activity, as well as effects on beta-cell survival were determined. Studies in mice were used to assess the impact of Ψ-xenin-6 on glucose homeostasis and satiety. Ψ-xenin-6 was resistant to murine plasma degradation. In BRIN-BD11 cells and isolated murine islets, Ψ-xenin-6 significantly stimulated insulin secretion, and prominently enhanced the insulinotropic actions of GIP. Xenin-6 and Ψ-xenin-6 had no impact on glucagon secretion, although xenin-6 partially reversed the glucagonotropic action of GIP. Further in vitro investigations revealed that, similar to GLP-1, Ψ-xenin-6 significantly augmented proliferation of human and rodent clonal beta-cells, whilst also fully protecting against cytokine-induced beta-cell cytotoxicity, with greater potency than xenin-25 and xenin-6. When administered to mice in combination with glucose, Ψ-xenin-6 significantly reduced glucose levels and enhanced glucose-induced insulin release, with a duration of biological action beyond 8 h. Ψ-xenin-6 also significantly enhanced the glucose-lowering action of GIP in vivo. In overnight fasted mice, Ψ-xenin-6 exhibited satiety actions at both 25 and 250 nmol/kg. These data demonstrates that Ψ-xenin-6 is a metabolically stable C-terminal fragment analogue of xenin-25, with a metabolic action profile that merits further study as a potential antidiabetic compound. •Xenin is a gut peptide that is metabolised to bioactive fragments such as xenin-6.•Ψ-xenin-6 is an enzymatically stable, long-acting xenin-6 analogue.•Ψ-xenin-6 augments insulin secretion and potentiates GIP-induced insulin release.•Ψ-xenin-6 has positive effects on beta-cell apoptosis and proliferation.•Ψ-xenin-6 improves glucose homeostasis and insulin secretion in mice.</description><subject>Animals</subject><subject>Beta-cell</subject><subject>Cell Line</subject><subject>Diabetes</subject><subject>Glucagon</subject><subject>Glucagon - metabolism</subject><subject>Glucose - pharmacology</subject><subject>Humans</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Insulin</subject><subject>Insulin Secretion - drug effects</subject><subject>Insulin-Secreting Cells - metabolism</subject><subject>Mice</subject><subject>Neurotensin - chemistry</subject><subject>Neurotensin - pharmacology</subject><subject>Xenin-25</subject><subject>Xenin-6</subject><issn>0303-7207</issn><issn>1872-8057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcuOFCEUhonROO3oA7gxLF1MtVy6KCquTGe8JJO40TWh4aB0gCqBMtPzBL6Az-UrSadmXLoiwH--k3M-hF5SsqWEijfHbTSwZYSOW0pJz_gjtKFyYJ0k_fAYbQgnvBsYGS7Qs1KOhJChZ_IpuuCU94xwuUG_r50DUwueHNYJQ7o7RV290SGccKn6EADvuwo5-qQD_g63ei6w2GmGuXoL2GX9LUKq-OGhgW4h-dSx_gr_-dWtF3GFp4RnnUyGMx_7EqBityRTffvRyeIIrd8UfInP0ROnQ4EX9-cl-vr--sv-Y3fz-cOn_bubzvBR1DYm05QKa9lOCAqOG80PgzNu4AcwkjHLARxta3DaSDlwOUohRE_sbhQMOL9Er1funKcfC5Sqoi8GQtAJpqUoxoTgfCf7sUXpGjV5KiWDU3P2UeeTokSdbaijajbU2YZabbSaV_f45RDB_qt4WH8LvF0D0Ib86SGrYjwkA9bnZkXZyf8H_xeZI5yT</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Craig, S.L.</creator><creator>Gault, V.A.</creator><creator>McClean, S.</creator><creator>Hamscher, G.</creator><creator>Irwin, N.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4855-964X</orcidid></search><sort><creationdate>20191001</creationdate><title>Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism</title><author>Craig, S.L. ; Gault, V.A. ; McClean, S. ; Hamscher, G. ; Irwin, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-802a116dd24661ef3ca3b7fcf73bec822d3eef1030fac887389866650d4962e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Beta-cell</topic><topic>Cell Line</topic><topic>Diabetes</topic><topic>Glucagon</topic><topic>Glucagon - metabolism</topic><topic>Glucose - pharmacology</topic><topic>Humans</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Insulin</topic><topic>Insulin Secretion - drug effects</topic><topic>Insulin-Secreting Cells - metabolism</topic><topic>Mice</topic><topic>Neurotensin - chemistry</topic><topic>Neurotensin - pharmacology</topic><topic>Xenin-25</topic><topic>Xenin-6</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Craig, S.L.</creatorcontrib><creatorcontrib>Gault, V.A.</creatorcontrib><creatorcontrib>McClean, S.</creatorcontrib><creatorcontrib>Hamscher, G.</creatorcontrib><creatorcontrib>Irwin, N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular and cellular endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Craig, S.L.</au><au>Gault, V.A.</au><au>McClean, S.</au><au>Hamscher, G.</au><au>Irwin, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism</atitle><jtitle>Molecular and cellular endocrinology</jtitle><addtitle>Mol Cell Endocrinol</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>496</volume><spage>110523</spage><epage>110523</epage><pages>110523-110523</pages><artnum>110523</artnum><issn>0303-7207</issn><eissn>1872-8057</eissn><abstract>Xenin-25 undergoes rapid enzyme metabolism following secretion. Early studies demonstrated bioactivity of a C-terminal hexapeptide fragment of xenin-25, namely xenin-6, which were enhanced through introduction of a reduced N-terminal peptide bond, to yield Ψ-xenin-6. The present study was undertaken to define the biological actions and potential antidiabetic properties of Ψ-xenin-6. In vitro enzymatic stability, insulin and glucagon secretory activity, as well as effects on beta-cell survival were determined. Studies in mice were used to assess the impact of Ψ-xenin-6 on glucose homeostasis and satiety. Ψ-xenin-6 was resistant to murine plasma degradation. In BRIN-BD11 cells and isolated murine islets, Ψ-xenin-6 significantly stimulated insulin secretion, and prominently enhanced the insulinotropic actions of GIP. Xenin-6 and Ψ-xenin-6 had no impact on glucagon secretion, although xenin-6 partially reversed the glucagonotropic action of GIP. Further in vitro investigations revealed that, similar to GLP-1, Ψ-xenin-6 significantly augmented proliferation of human and rodent clonal beta-cells, whilst also fully protecting against cytokine-induced beta-cell cytotoxicity, with greater potency than xenin-25 and xenin-6. When administered to mice in combination with glucose, Ψ-xenin-6 significantly reduced glucose levels and enhanced glucose-induced insulin release, with a duration of biological action beyond 8 h. Ψ-xenin-6 also significantly enhanced the glucose-lowering action of GIP in vivo. In overnight fasted mice, Ψ-xenin-6 exhibited satiety actions at both 25 and 250 nmol/kg. These data demonstrates that Ψ-xenin-6 is a metabolically stable C-terminal fragment analogue of xenin-25, with a metabolic action profile that merits further study as a potential antidiabetic compound. •Xenin is a gut peptide that is metabolised to bioactive fragments such as xenin-6.•Ψ-xenin-6 is an enzymatically stable, long-acting xenin-6 analogue.•Ψ-xenin-6 augments insulin secretion and potentiates GIP-induced insulin release.•Ψ-xenin-6 has positive effects on beta-cell apoptosis and proliferation.•Ψ-xenin-6 improves glucose homeostasis and insulin secretion in mice.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>31352038</pmid><doi>10.1016/j.mce.2019.110523</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4855-964X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0303-7207
ispartof Molecular and cellular endocrinology, 2019-10, Vol.496, p.110523-110523, Article 110523
issn 0303-7207
1872-8057
language eng
recordid cdi_proquest_miscellaneous_2266334859
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Animals
Beta-cell
Cell Line
Diabetes
Glucagon
Glucagon - metabolism
Glucose - pharmacology
Humans
Hypoglycemic Agents - chemistry
Hypoglycemic Agents - pharmacology
Insulin
Insulin Secretion - drug effects
Insulin-Secreting Cells - metabolism
Mice
Neurotensin - chemistry
Neurotensin - pharmacology
Xenin-25
Xenin-6
title Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T02%3A49%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20an%20enzymatically%20stable%20C-terminal%20hexapseudopeptide%20fragment%20peptide%20of%20xenin-25,%20%CF%88-xenin-6,%20on%20pancreatic%20islet%20function%20and%20metabolism&rft.jtitle=Molecular%20and%20cellular%20endocrinology&rft.au=Craig,%20S.L.&rft.date=2019-10-01&rft.volume=496&rft.spage=110523&rft.epage=110523&rft.pages=110523-110523&rft.artnum=110523&rft.issn=0303-7207&rft.eissn=1872-8057&rft_id=info:doi/10.1016/j.mce.2019.110523&rft_dat=%3Cproquest_cross%3E2266334859%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2266334859&rft_id=info:pmid/31352038&rft_els_id=S0303720719302254&rfr_iscdi=true